119.95
+2.78(+2.37%)
Currency In USD
Address
700 Saginaw Drive
Redwood City, CA 94063
United States of America
Phone
650 481 6801
Website
Sector
Healthcare
Industry
Biotechnology
Employees
616
First IPO Date
February 13, 2020
| Name | Title | Pay | Year Born |
| Mark A. Goldsmith | Chief Executive Officer, President & Chairman | 1.35M | 1962 |
| Xiaolin Wang | Executive Vice President of Development | 701,200 | 1970 |
| Jack Anders | Chief Financial Officer | 725,633 | 1977 |
| Margaret A. Horn | Chief Operating Officer | 897,933 | 1963 |
| Stephen Kelsey Path. | President of Research & Development | 951,933 | 1961 |
| Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board | 0 | 1981 |
| Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
| Walter Reiher | Chief Information Officer | 0 | N/A |
| Jan Smith | Chief Scientific Officer | 0 | N/A |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.